Neil Braunstein
Rheumatology · Las Vegas, NVNPI 1265434716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by UCB, Inc. at 36.5% of the total.
Across 144 payments — averaging $39.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- AbbVie$1K
- Novartis$463
- Amgen$411
- Boehringer Ingelheim$260
- AstraZeneca$244
- plus $884 from 12 others
What the payments were for
- Food & beverage$5,616100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 68 | $2,053 |
| AbbVie | 17 | $1,302 |
| Novartis | 8 | $463 |
| Amgen(2 entities) | 8 | $411 |
| Boehringer Ingelheim | 4 | $260 |
| AstraZeneca | 2 | $244 |
| Lilly USA, LLC | 6 | $241 |
| GSK | 5 | $176 |
| Novo Nordisk | 6 | $101 |
| Pfizer | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Johnson & Johnson | 2 | $40 |
| Lifescan, Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Abbott | 1 | $22 |
| Sanofi | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,616 in reported general payments places this provider in the 70th percentile of 43 rheumatology providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $96,711 |
| Hydroxychloroquine Sulfate | 117 | $3,428 |
| Leflunomide | 45 | $1,682 |
| Azathioprine | 35 | $1,079 |
| MethotrexateMethotrexate Sodium | 103 | $1,009 |
| Gabapentin | 53 | $831 |
| Prednisone | 116 | $646 |
| Sulfasalazine | 25 | $506 |
| Folic Acid | 56 | $475 |
| Leucovorin Calcium | 14 | $384 |
| Duloxetine Hcl | 16 | $285 |
| Tizanidine Hcl | 16 | $231 |
| Meloxicam | 28 | $186 |
| Allopurinol | 17 | $158 |
| Alendronate Sodium | 15 | $109 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Las Vegas
- Ewa OlechLas Vegas$287K
- Walter ChathamLas Vegas$197K
- George KellyLas Vegas$185K
- Nasim DaoudLas Vegas$109K
- William KimLas Vegas$16K
- Aida LoudyiLas Vegas$10K
- Tudor JianuLas Vegas$8K
- Khalil Ibrahim BourjiLas Vegas$7K
- Michael CliffordLas Vegas$4K
- Chen TangLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.